Corporate, Microbial genomics

Illumina statement on novel coronavirus

Illumina has enacted precautionary measures focusing on the health and safety of our employees, families, customers and communities

Illumina statement on novel coronavirus
March 17, 2020

With the global spread of SARS-CoV-2, Illumina has enacted precautionary measures focusing on the health and safety of our employees, families, customers and communities. To help protect Illumina employees and business continuity, we have proactively implemented efforts including limiting travel and attendance at meetings and conferences, and allowing employees to work remotely, where possible. We are closely monitoring the situation and will update our action plan to protect employees, keep customers running and support efforts to minimize the spread of the virus. To date, we have not experienced sustained supply chain or other operational delays. We will continue to monitor and update as the situation evolves, balancing the safety of our employees and the needs of our customers. 

 

 

Recent articles

How genomics can help detect drug-resistant TB earlier
Video: How genomics can help detect drug-resistant TB earlier
In Canada, researching the use of AI to accelerate answers for rare disease
In Canada, researching the use of AI to accelerate answers for rare disease
How Singapore is solidifying its role at the forefront of global genomics
How Singapore is solidifying its role at the forefront of global genomics